Kodiak Sciences (KOD) Accumulated Expenses (2017 - 2026)
Kodiak Sciences' (KOD) quarterly Accumulated Expenses came in at $9.2 million in Q1 2026, up 44.02% YoY from $6.4 million in Q1 2025, and up 18.28% on a QoQ basis from $7.8 million in Q4 2025.
Kodiak Sciences (KOD) Accumulated Expenses (2017 - 2026) Analysis & Trends
Kodiak Sciences (KOD) has 10 years of Accumulated Expenses data on file, last reported at $9.2 million in Q1 2026.
- Quarterly Accumulated Expenses rose 44.02% year-over-year to $9.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.2 million (up 44.02% YoY) and the FY2025 annual result came in at $7.8 million, up 261.73% from the prior year.
- Accumulated Expenses rose to $9.2 million in Q1 2026, from $7.8 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $43.2 million in Q2 2022 to a low of $2.1 million in Q4 2024.
- A 5-year average of $10.0 million and a median of $7.8 million in 2025 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2022 — Accumulated Expenses soared 1160.09% — and 2023, when it tumbled 91.82%.
- Tracing KOD's Accumulated Expenses over 5 years: stood at $6.0 million in 2022, then soared by 44.9% to $8.7 million in 2023, then slumped by 75.2% to $2.1 million in 2024, then jumped by 261.73% to $7.8 million in 2025, then increased by 18.28% to $9.2 million in 2026.
- The last three Accumulated Expenses figures came in at $9.2 million (Q1 2026), $7.8 million (Q4 2025), and $20.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Kodiak Sciences | 2.60 Bn | 2.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.32 Mn |
| Mar 31, 2026 | 9.19 Mn |
| Dec 31, 2025 | 7.77 Mn |
| Sep 30, 2025 | 20.31 Mn |
| Jun 30, 2025 | 4.00 Mn |
| Mar 31, 2025 | 6.38 Mn |
| Dec 31, 2024 | 2.15 Mn |
| Sep 30, 2024 | 2.63 Mn |
| Jun 30, 2024 | 9.44 Mn |
| Mar 31, 2024 | 12.77 Mn |
| Dec 31, 2023 | 8.66 Mn |
| Sep 30, 2023 | 6.31 Mn |
| Jun 30, 2023 | 3.53 Mn |
| Mar 31, 2023 | 4.12 Mn |
| Dec 31, 2022 | 5.98 Mn |
| Sep 30, 2022 | 14.30 Mn |
| Jun 30, 2022 | 43.16 Mn |
| Mar 31, 2022 | 9.52 Mn |
| Dec 31, 2021 | 6.04 Mn |
| Sep 30, 2021 | 3.39 Mn |